Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIVEL: Switch vs GDI for Aromatase Inhibitor Side Effects in Breast Cancer
NCT07071038Phase 2Recruiting
- Sponsor
- Dartmouth Health
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of anastrozole, exemestane in breast cancer, sponsored by Dartmouth Health. Started Oct 2025; status: recruiting.
02
Drugs
anastrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07071038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071038.